Renal Cell Carcinoma | Access and Reimbursement | EU5 | 2017
The renal cell carcinoma drug market in Europe is increasingly competitive. Angiogenesis inhibitors (such as Pfizer’s Sutent and Novartis’s Votrient) and mTOR inhibitors (Pfizer’s Torisel and Novartis’s Afinitor) have long dominated the treatment algorithm, and in 2016, two novel antiangiogenic therapies (Eisai’s Kisplyx and Ipsen’s Cabometyx) and one immune checkpoint inhibitor (Bristol-Myers Squibb’s Opdivo) also gained marketing authorization. The approval of Kisplyx, specifically in combination with Afinitor, marked the first targeted therapy combination to enter the renal cell carcinoma market. With escalating drug costs amid tight healthcare budgets, robust demonstration of cost-effectiveness is crucial for reimbursement, while optimizing uptake thereafter is a tactical challenge. Drawing on prescriber and payer insight, this research analyzes the evolving treatment and market access landscape for renal cell carcinoma in the EU5.
Questions Answered
- What clinical and cost/payer-related drivers and barriers shape oncologists’ prescribing decisions for renal cell carcinoma? How do these factors vary at national, regional, and local levels in each country under study?
- How are payers reacting to the entry of novel premium-priced renal cell carcinoma agents? What cost-containment strategies do they employ and how will these evolve?
- What role will evolving healthcare reforms play in differentiating the reimbursement of high-cost therapies versus currently available agents?
- What clinical benefits are sought by oncologists and payers for emerging therapies in renal cell carcinoma? How are these ranked against pharmacoeconomic advantages?
Product description
Access & Reimbursement: Provides in-depth insight regarding the impact of payer policy on physician prescribing behavior so you can build your market access strategy and optimize your brand positioning.
